Rix, Uwe

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences

Chronic Myeloid Leukemia TreatmentsMast cells and histamine

Cited by 284

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 256

Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition

Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 106

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., et al. (2017) · ACS Chemical Biology

Microtubule and mitosis dynamicsCancer-related Molecular Pathways

Cited by 77

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Peter, B., Winter, G. E., Blatt, K., Bennett, K. L., Stefanzl, G., Rix, U., Eisenwort, G., Hadzijusufovic, E., Gridling, M., Dutreix, C., et al. (2016) · Leukemia

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 63